Cytokines as Active Factors in Focal Segmental Glomerulosclerosis

Published on 02/05/2016 by admin

Filed under Nephrology

Last modified 03/05/2016

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 260 times

35.
Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res. 2008;151:288–92. doi:10.​1016/​j.​trsl.​2008.​04.​001.PubMed
36.
McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433–8.PubMed
37.
Dileepan KN, Sharma R, Stechschulte DJ, Savin VJ. Effect of superoxide exposure on albumin permeability of isolated rat glomeruli. J Lab Clin Med. 1993;121:797–804.PubMed
38.
Charba DS, Wiggins RC, Goyal M, Wharram BL, Wiggins JE, McCarthy ET, et al. Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb)). Am J Physiol Renal Physiol. 2009;297:F138–44. doi:10.​1152/​ajprenal.​00122.​2008.PubMedCentralPubMed
39.
Adler S, Sharma R, Savin VJ, Abbi R, Eng B. Alteration of glomerular permeability to macromolecules induced by cross-linking of beta 1 integrin receptors. Am J Pathol. 1996;149:987–96.PubMedCentralPubMed
40.
Aggarwal N, Batwara R, McCarthy ET, Sharma R, Sharma M, Savin VJ. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis. 2007;50:826–9.PubMed
41.
Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002;13:1946–52.PubMed
42.
Srivastava T, Garola RE, Kestila M, Tryggvason K, Ruotsalainen V, Sharma M, et al. Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol. 2006;21:711–8.PubMed
43.
Sgambat K, Banks M, Moudgil A. Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2013;28:2131–5. doi:10.​1007/​s00467-013-2539-z.PubMed
44.
De Smet E, Rioux JP, Ammann H, Deziel C, Querin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant. 2009;24:2938–40. doi:10.​1093/​ndt/​gfp278.PubMed
45.
Kopac M, Meglic A, Rus RR. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Apher Dial. 2011;15:269–72. doi:10.​1111/​j.​1744-9987.​2011.​00949.​x.PubMed
46.
Jhaveri KD, Naber TH, Wang X, Molmenti E, Bhaskaran M, Boctor FN, et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation. 2011;91:e35–6. doi:10.​1097/​TP.​0b013e3182088b67​.PubMed
47.
Mishra OP, Singh AK. Galactose treatment in focal and segmental glomerulosclerosis. Pediatr Nephrol. 2014;29:935. doi:10.​1007/​s00467-013-2731-1.PubMed
48.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.PubMed
49.
Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003–17.PubMed
50.
Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 1992;42:1457–61.PubMed
51.
Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, Mathieson PW, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol. 2003;284:F1263–73.PubMed
52.
Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol. 1995;268:F240–50.PubMed
53.
Klanke B, Simon M, Rockl W, Weich HA, Stolte H, Grone HJ. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant. 1998;13:875–85.PubMed
54.
Webb NJ, Watson CJ, Roberts IS, Bottomley MJ, Jones CA, Lewis MA, et al. Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int. 1999;55:1063–71.PubMed
55.
Laflam PF, Garin EH. Effect of tumor necrosis factor alpha and vascular permeability growth factor on albuminuria in rats. Pediatr Nephrol. 2006;21:177–81.PubMed
56.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–16.PubMedCentralPubMed
57.
Buy Membership for Nephrology Category to continue reading. Learn more here